Altor BioScience Corporation Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
Published: Dec 20, 2007
MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation today announced it has completed treatment of the first cohort of metastatic cancer patients in a Phase I/IIa clinical trial with the Company's lead drug candidate, ALT-801. Altor also reported that the expansion phase of this clinical trial will be supported in part through funding awarded by the U.S. Food and Drug Administration (FDA) Orphan Products Development (OPD) Grant Program. ALT-801 is a novel tumor-targeted immunotherapeutic designed to improve on the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).